ONKOLOGIEFrauenklinik Taxisstraße
2018
Neues aus San Antonio2017
Therapie des frühen Mammakarzinoms(neo‐)adjuvant
C.A. Hanusch
ONKOLOGIEFrauenklinik Taxisstraße
2018
Topics 1
• GS3‐05: Survival analysis of the prospectively randomized phase III GeparSepto trial
• GS3‐04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeksversus 1 year, combined with adjuvant taxane‐anthracycline chemotherapy, for earlyHER2‐positive breast cancer (the SOLD study).
• Incidence and management of diarrhea with adjuvant Pertuzumaband Trastuzumab in HER2‐positive breast cancer
ONKOLOGIEFrauenklinik Taxisstraße
2018
Topics 2• Pharmacokinetic results of a subcutaneous injection of Trastuzumab into the thigh versus into the abdominal wall in patients with HER2‐positive primary breast cancer (BC) treated within the neo‐/adjuvant GAIN‐2 study
• Efficacy and safety of subcutaneous or intravenous Trastuzumab in patients with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH study
• A phase Ib dose‐finding study of subcutaneous Pertuzumab in combination with subcutaneous Trastuzumab in healthy male volunteers and female patients with early breast cancer
ONKOLOGIEFrauenklinik Taxisstraße
2018
GS3‐05: Survival analysis of the prospectively randomized phase III GeparSepto trial
GeparSepto: Überträgt sich die signifikant höhere pCR Rate mit nab-Pac in ein besseres DFS?
ONKOLOGIEFrauenklinik Taxisstraße
2018
Schneeweiss A, et al. SABCS 2017 (GS3-05)
ONKOLOGIEFrauenklinik Taxisstraße
2018
ONKOLOGIEFrauenklinik Taxisstraße
2018
ONKOLOGIEFrauenklinik Taxisstraße
2018
Schneeweiss A, et al. SABCS 2017 (GS3-05)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Schneeweiss A, et al. SABCS 2017 (GS3-05)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Schneeweiss A, et al. SABCS 2017 (GS3-05)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Schneeweiss A, et al. SABCS 2017 (GS3-05)
ONKOLOGIEFrauenklinik Taxisstraße
2018
ONKOLOGIEFrauenklinik Taxisstraße
2018
ONKOLOGIEFrauenklinik Taxisstraße
2018
Schneeweiss A, et al. SABCS 2017 (GS3-05)
ONKOLOGIEFrauenklinik Taxisstraße
2018
pCR Rate gesteigert mit nabPaclitaxel vs. lösl. Paclitaxel als Teil einer sequenziellen Anthracyclin/Taxan‐basierten Chemotherapie
Höhere pCR‐Rate übersetzt sich in ein signifikant und klinisch relevant verbessertes rezidivfreiesÜberleben (HR=0.69, log rank p=0.0044)
Auch Pat. mit Ki67 <20% bzw. non‐pCR profitieren bez. DFS von nab‐Paclitaxel
Rate peripherer Neuropathien unter nabPaclitaxel nach Dosisreduktion gesenkt:Grad ¾: 150/ 125 (mg/m2 KOF) 15%/ 8% (nach 464 rekrutierten Pat.)
Fazit
ONKOLOGIEFrauenklinik Taxisstraße
2018
A randomized phase III study of adjuvant Trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant Taxane‐Anthracycline chemotherapy, for
early HER2‐positive breast cancer The Synergism Or Long Duration (SOLD)
trialJoensuu H et al. Oral Session – General Session 3
Abstract No. GS3‐04
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Hypothesis
Administration of Trastuzumab concomitantly with a Taxane for a brief time period is not inferior in terms of DFS as compared with the standard treatment*, and may be less cardiotoxic
*Standard: Chemotherapy plus 12 months of anti‐HER2‐directed treatment ± endocrine therapy
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐0417
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Design
*Wkly iv, or 3‐wkly either iv or sc; **14 times 3 weekly, either iv or sc
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
In both groups:
• Locoregional RT given according to the institutional practice
• Endocrine therapy for a minimum of 5 yrs when cancer ER/PR + ve
Docetaxel (D)
80/100 mg/m2
iv 3‐wkly
F600E75C600iv 3‐wkly
Trastuzumab (T)
T for 9 wks*
T for 9 wks* T to complete 1 year of administration**
DFEC
D D
D D D
FEC
FEC
FEC
FEC
FEC
R
18
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Patient disposition
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐0419
Category 9 weeksno. (%)
1 yearno. (%)
Randomized (Jan 2008 to Dec 2014) 1,087 1,089
Included ITT Population* 1,085 1,089
Withdrew consent 0 (0) 0 (0)
Had distant metastases at study entry 2 (0) 0 (0)
Received study treatment (Safety Population) 1,084 1,089
*ITT, Intention to treat
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Key baseline characteristics
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐0420
Characteristic 9-week group(n=1,085)
1-year group(n=1,089)
Median age (range) – years (range) 56 (23-82) 56 (27-79)
Premenopausal 33% 33%
Breast tumor diameter≤10 mm 12% 14%11-21 mm 44% 42%21-50 mm 41% 42%>50 mm 3% 3%
Axillary lymph nodes with cancer0 60% 60%1-3 30% 29%>3 11% 11%
Ductal histological type 92% 92%Estrogen receptor-positive 66% 66%Progesterone receptor-positive 46% 47%
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – DFS events and deaths (ITT)
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐0421
Event9-wk group(n=1,085)
n (%)
1-yr group(n=1,089)
n (%)Any recurrence or death 140 (13) 105 (10)
Distant recurrence 73 (7) 61 (6)Locoregional recurrence 17 (2) 13 (1)Contralateral BC 15 (1) 7 (1)Second cancer 27 (3) 24 (2)Death without cancer 14 (1) 5 (0)
Death from any cause 58 (5) 44 (4)Death from BC 34 (3) 33 (3)Death from another cause 24 (2) 11 (1)
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Disease‐free survival
22 Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
Alive, norecurren
ce(%
)
90.5%*
88.0%*
HR 1.39 (90% Cl 1.12‐1.72)
Non‐inferiority could not be demonstrated
51 weeks9 weeks
Years
Non‐inferiority margin 1.385
Hazard Ratio
• Chemo: 3 x Doc q3w 3 x FEC q3w, N=2,176
• Non‐inferiority instead of superiority study design
*5‐year DFS estimate
Number at risk10851089
10131047
707742
373394
7682
00
0 2 4 6 8 10 0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8
0
20
40
60
80
100
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Overall survival
23 Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
Prop
ortio
n alive(%
)
Number at risk10851089
10471078
761786
408421
8187
00
95.9%*
94.7%*
HR 1.36 (90% Cl 0.98‐1.89)
Years
*5‐year survival estimate
51 weeks9 weeks
ONKOLOGIEFrauenklinik Taxisstraße
2018
HR 1.24 (90% Cl 0.93‐1.65)
SOLD – Distant disease‐free survival
24 Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
94.2%*
93.2%*Prop
ortio
n with
outd
istant
recurren
ce(%
)
*5‐year DDFS estimate
51 weeks9 weeks
YearsNumber at risk
10851089
10251056
723760
393409
8083
00
ONKOLOGIEFrauenklinik Taxisstraße
2018
Subgroup Hazard Ratio(90% Cl)
p (interaction)
ER status NegativePositive
1.57 (1.14‐2.17)1.28 (0.96‐1.69) 0.424
Docetaxel dose 80 mg/m2
100 mg/m21.66 (1.30‐2.11)0.67 (0.41‐1.10) 0.007
Nodes with cancer 01‐33+
1.31 (0.95‐1.80)1.83 (1.22‐2.74)1.24 (0.82‐1.85) 0.460
Centre accrual <100 patients≥100 patients
1.40 (1.06‐1.83)1.37 (0.98‐1.93) 0.949
Age <50 yrs≥50 yrs
1.08 (0.76‐1.53)1.61 (1.23‐2.11) 0.137
Stage IIIIII
1.46 (0.96‐2.22)1.54 (1.12‐2.11)1.21 (0.81‐1.79) 0.724
SOLD – Predefined subgroup analyses for DFS
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐0425
Favors 9 weeks Favors 1-year10.5 1.5 20 2.5 3
ONKOLOGIEFrauenklinik Taxisstraße
2018
Prop
ortio
n alivewith
outrecurrence(%
)
SOLD – DFS: Docetaxel dose 80 mg/m2
26 Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
91.3%*
86.8%*
HR 1.66 (90% Cl 1.30‐2.11)
YearsNumber at risk843835
765808
545568
309317
7077
00
*5‐year DFS estimate
51 weeks9 weeks
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – DFS: Docetaxel dose 100 mg/m2
27 Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
92.2%*
87.8%*
242254
228239
162174
6477
55
00
Prop
ortio
n alivewith
outrecurrence(%
)
*5‐year DFS estimate
51 weeks9 weeks
Number at risk
HR 0.71 (90% Cl 0.44‐1.14)
Years
ONKOLOGIEFrauenklinik Taxisstraße
2018
• Chemotherapy‐related toxicity generally similar and expected in the 2 groups
SOLD – Treatment safety
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
9-weekgroupn (%)
1-yeargroupn (%)
Discontinued Chemotherapy 44 (4.1) 51 (4.7)
Discontinued Trastuzumab 96 (8.9)-53% for toxicity
217 (19.9)-66% for toxicity
Died from treatment-related cause 2 (0.2) 2 (0.2)
28
ONKOLOGIEFrauenklinik Taxisstraße
2018
• Less cardiac toxicity was observed in the 9‐week group
SOLD – Cardiac safety
*Any Gr. 3 or 4 cardiac event; symptomatic cardiac failure; cardiac failure requiring medical management; LVEF decrease >10 percentage points and to a value <50%; LVEF decrease to <45% from any baseline value,
** p=0.012; ***p=0.046
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
Event 9-week groupn (%)
1-year groupn (%)
Any protocol-defined cardiac adverse event* 22 (2.0) 42 (3.9)**
Congestive heart failure 21 (1.9) 36 (3.3)***
29
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Mean LVEF stratified by the treatmentgroup
LVEF, Left ventricular ejection fraction
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
LVEF (%
)
p<0.001
Time after study entry
9 weeks
51 weeks
30
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Conclusions
• Non‐inferiority of 9‐weeks of adjuvant Trastuzumab plus Chemotherapy could not be demonstrated as compared to 1‐year of Trastuzumab plus Chemotherapy in terms of DFS
• Patients treated with the 9‐week duration had fewer cardiac events and had the LVEF better maintained
• Docetaxel dosing with Trastuzumab requires further study• Chemotherapy plus 1‐year of anti‐HER2 therapy should remain the standard
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐0431
ONKOLOGIEFrauenklinik Taxisstraße
2018
Incidence and management of diarrheawith adjuvant Pertuzumab and
Trastuzumab in HER2‐positive breast cancer
Bines J et al. Poster Session 1 – Treatment: Adjuvant Therapy
Abstract No. P1‐13‐07
ONKOLOGIEFrauenklinik Taxisstraße
2018
Mod. Bines J et al. SABCS 2017, Poster Session 1 – Treatment: Adjuvant Therapy, Abstract No. P1‐13‐0733
APHINITY – Inzidenz der Diarrhoe nachTherapiezyklus
De Azambuja E et al., SABCS 2017
Targeted treatment cycle
Percen
tage of p
atients w
ith an even
t
Pertuzumab + Trastuzumab + Chemotherapy
Placebo + Trastuzumab + Chemotherapy
2,3642,335
2,2532,241
2,2332,225
2,2652,257
1,6581,700
2,1852,190
2,0512,051
2,3062,302
2,2462,231
2,3292,317
2,2852,281
2,2102,211
2,1932,194
2,1512,169
2,1362,159
2,1092,129
2,1652,178
2,2002,200
No. at risk
ONKOLOGIEFrauenklinik Taxisstraße
2018
APHINITY – Inzidenz der Diarrhoe nach Therapiezyklus und Art der Chemotherapie
Mod. Bines J et al. SABCS 2017, Poster Session 1 – Treatment: Adjuvant Therapy, Abstract No. P1‐13‐0734
De Azambuja E et al., SABCS 2017
Targeted treatment cycle
1,8341,824528510
1,7551,751496489
1,7411,742490482
1,7641,765499491
1,3121,336345364
1,7031,713480476
1,6081,602441448
1,7981,806506495
1,7511,744493486
1,8131,815514501
1,7831,788500492
1,7211,730487480
1,7081,716483477
1,6771,692472476
1,6661,685468473
1,6461,659461469
1,6891,701474476
1,7131,719485480
No. at risk
Pertuzumab + Trastuzumab + Anthracycline
Placebo + Trastuzumab + Anthracycline
Pertuzumab + Trastuzumab + Non‐Anthracycline
Placebo + Trastuzumab + Non‐Anthracycline
Percen
tage of p
atients w
ith an even
t
ONKOLOGIEFrauenklinik Taxisstraße
2018
APHINITY – Inzidenz und Management der Diarrhoe
Mod. Bines J et al. SABCS 2017, Poster Session 1 – Treatment: Adjuvant Therapy, Abstract No. P1‐13‐0735
De Azambuja E et al., SABCS 2017All presented data based on the preferred term “diarrhea“; *The incidence of diarrhea is based on anthracycline‐based chemotherapy only as no Pertuzumab or Placebo was given concurrently with an
Anthracycline. ¹Docetaxel only in the Non‐Anthracycline groups.
Anthracycline-based chemotherapy Non-Anthracycline-based chemotherapy
Pertuzumab + Trastuzumab n=1,834
Placebo + Trastuzumab n=1,894
Pertuzumab + Trastuzumab n=528
Placebo + Trastuzumab n=510
Incidence and severityTotal number of patients with at least one event (%) 1,235 (67.3) 772 (40.8) 447 (84.7) 314 (61.6)Total number of events 2,527 1,282 883 508Total number of patients with at least one NC1-CTCAE grade ≥3 event (%) 137 (7.5) 59 (3.1) 95 (18.0) 31 (6.1)
Total number of NCI-CTCAE grade ≥3 events 147 60 113 35Treatment period, total number of patients with at least one event (%)Anthracycline* 296 (16.1) 278 (14.7) – –HER2-targeted therapy + Taxane¹ 1,006 (54.9) 513 (27.1) 444 (84.1) 301 (59.0)HER2-targeted treatment post-chemotherapy 373 (20.3) 175 (9.2) 55 (10.4) 46 (9.0)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Safety of adjuvant treatment with Pertuzumab plus Trastuzumab after neoadjuvant Anthracycline‐based
chemotherapy in patients with HER2‐positive localized breast cancer: Updated results from the
BERENICE study
Dang C et al. Poster Session 5 – Treatment: Her2‐targeted therapy
Abstract No. P5‐20‐04
ONKOLOGIEFrauenklinik Taxisstraße
2018
Cohort A(ddAC TPH)
Cohort B(FEC DPH)
Overalltreatment period n=199
Adjuvant treatment period n=181
Overall treatment period n=198
Adjuvant treatment period n=190
Any AE 198 (99.5) 171 (94.5) 198 (100.0) 171 (90.0)Grade ≥3 AE 109 (54.8) 23 (12.7) 126 (63.6) 40 (21.1)Serious AE 54 (27.1) 15 (8.3) 61 (30.8) 17 (8.9)
AE leading to P or H discontinuation 19 (9.5) 9 (5.0) 14 (7.1) 11 (5.8)
Diarrhea (any grade) 144 (72.4) 26 (14.4) 148 (74.7) 45 (23.7)Diarrhea (grade ≥3) 6 (3) 0 (0) 22 (11.1) 2 (1.1)
Mod. Dang C et al. SABCS 2017, Poster Session 5 – Treatment: Her2‐targeted therapy, Abstract No. P5‐20‐04 37
BERENICE StudieAdjuvantes Trastuzumab/Pertuzumab nach anthrazyklinhaltiger NACT (ddAC q2w Pacli q1w vs. FEC q3w Docetaxel q3w, N=397)
Data are number of patients (%).AE. adverse events; ddAC. dose‐dense Doxorubicin plus Cyclophosphamide; DPH. Docetaxel. Pertuzumab. and Trastuzumab; FEC. Fluorouracil. Epirubicin. and Cyclophosphamide; TPH. Paclitaxel,
Pertuzumab. and Trastuzumab.
General AEs (safety population)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Take Home Message
38
• Die Rate der Diarrhoe unter CTX plus Trastuzumab + Pertuzumab ist im Vgl. zu Trastuzumab erhöht
• Erhebliche Verbesserung nach Absetzen der CTX• APHINITY: Gesteigerte Diarrhoe unter Anthrazyklin‐freier CTX durch den alleinigen Einsatz von Docetaxel bedingt
ONKOLOGIEFrauenklinik Taxisstraße
2018
Pharmacokinetic results of a subcutaneous injection of Trastuzumab into the thigh versus into the abdominal wall in patients with HER2‐positive primary breast cancer (BC) treated within the neo‐/adjuvant GAIN‐2 study
Möbus V et al. Poster Session 5 – Treatment: Her2‐targeted therapyAbstract No. P5‐20‐09
ONKOLOGIEFrauenklinik Taxisstraße
2018
40
GAIN‐2 StudiePK Resultate s.c. Applikation von Trastuzumab
Mod. Möbus V et al. SABCS 2017, Poster Session 5 – Treatment: Her2‐targeted therapy, Abstract No. P5‐20‐09
N=2886
Neo
‐/Ad
juvant
(∑ 100
0 pa
ents)
Trastuzumab i.v.**
Pertuzumab i.v.*
Pertuzumab i.v.*
Trastuzumab i.v.**
EpirubicinStarting dose. 90 mg/m² q2wDose levels (min./max.)‐ Level – 3: 38 mg/m² q2w‐ Level + 2: 120 mg/m² q2w
CyclophosphamideStarting dose: 600 mg/m² q2wDose levels (min./max.)‐ Level – 3: 450 mg/m² q2w‐ Level +2: 1200 mg/m² q2w
DocetaxelStarting dose: 75 mg/m² q2wDose levels (min./max.)‐ Level – 1: 60 mg/m² q2w‐ Level + 2: 100 mg/m² q2w
Epirubicin150 mg/m²
q2w
nab‐Paclitaxel330 mg/m²
q2w
Cyclophos‐phamide
2000 mg/m² q2w
N=220
1 week
rest
*Pertuzumab i.v.(if HER2‐positive and neoadjuvant): Starting dose 840 mg q3w, thereafter 420 mg q3w.
**Trastuzumab i.v.(if HER2‐positive and neoadjuvant or adjuvant): Starting dose 8 mg/kg BW q3w, thereafter 6 mg/kg BW q3w
***Therapy durationTrastuzumab i.v. and s.c. totally 1 year
E E E nP nP nP C C C
E E ED D D D
R
EC C C C
3 weeks
Trastuzumab s.c.Thigh
Trastuzumab s.c.Abdominal wall
Trastuzumab s.c.600 mg q3w***
Trastuzumab s.c.600 mg q3w.***
R
ONKOLOGIEFrauenklinik Taxisstraße
2018
Mod. Möbus V et al. SABCS 2017, Poster Session 5 – Treatment: Her2‐targeted therapy, Abstract No. P5‐20‐09 41
GAIN‐2 Studie – PK Resultate s.c. Applikation von Trastuzumab
Mean plasma concentration‐time profile of the s.c. Trastuzumab
Concen
tration (ug/ml)
Time (days)
Thigh
Abdw
ONKOLOGIEFrauenklinik Taxisstraße
2018
Take Home Message – GAIN‐2
42
• Bestätigung der besseren Bioverfügbarkeit und daraus resultierenden Plasmaspiegel nach Applikation von TrastuzumabSC in den Oberschenkel vs. die Bauchdecke
• Damit Bestätigung der Zulassung von Trastuzumab SC
ONKOLOGIEFrauenklinik Taxisstraße
2018
Efficacy and safety of subcutaneous or intravenous Trastuzumab in patients with HER2‐positive early
breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label,
randomized HannaH study
Jackisch C et al., Poster Discussion – Novel Drugs / Predicting Response for HER2+ Breast Cancer
Abstract No. PD3‐11
ONKOLOGIEFrauenklinik Taxisstraße
2018
HannaH Trial – Trastuzumab s.c., 5‐J‐FU, finale AnalyseEFS by tpCR status (ITT population)
Mod. Jackisch C et al. SABCS 2017, Poster Discussion – Novel Drugs / Predicting Response for HER2+ Breast Cancer, Abstract No. PD3‐11
EFS, event‐free‐survival; H IV, intravenous Trastuzumab; H SC, subcutaneous Trastuzumab: ITT, intent‐to‐treat population: tpCR, total pathologic complete response
TreatmentH IV / tpCRH SC / tpCRH IV / non‐tpCRH SC / non‐tpCR
Estim
ated
Proba
bility
Months
94203108186
51524244
93170105159
741077992
70997687
7612486116
8114398133
0000
No. at risk
6‐year event‐free rate (95% Cl)
H IV H SC
tpCR 0.83(0.76, 0.91)
0.82(0.74, 0.89)
No tpCR 0.57(0.49, 0.64)
0.54(0.47, 0.62)
44
ONKOLOGIEFrauenklinik Taxisstraße
2018
Take Home Message – HannaH
45
• Überlebensvorteil (EFS/OS) nach pCR bestätigt• Konsistente Resultate hinsichtlich der Äquieffektivität von Trastuzumab s.c. vs. i.v.
• Keine neuen Safety‐Signale
ONKOLOGIEFrauenklinik Taxisstraße
2018
A phase Ib dose‐finding study of subcutaneous Pertuzumab in combination with subcutaneous Trastuzumab in healthy male volunteers and female patients with early breast cancer
Kirschbrown WP et al. Poster Session – 5 Treatment: Her2‐targeted therapy (presenter:
Whitney P)Abstract No. P5‐20‐07
ONKOLOGIEFrauenklinik Taxisstraße
2018
Take Home Message – Pertuzumab s.c.
47
• Pertuzumab s.c. ähnliche PK wie Pertuzumab i.v.• Kombination von Pertuzumab s.c. und Trastuzumab s.c. ohne beeinträchtigende Wirkung aufeinander
• Phase‐3‐Studie mit dualer Blockade s.c. als fixe Dosis in Planung– FPI Juni 2018
ONKOLOGIEFrauenklinik Taxisstraße
2018
Vielen Dank für Ihre Aufmerksamkeit!
ONKOLOGIEFrauenklinik Taxisstraße
2018